Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
Open Virol J. 2010 Jun 18;4:103-8. doi: 10.2174/1874357901004030103.

Herpesvirus vectors for therapy of brain tumors.

Author information

  • 1Department of Pediatrics, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL 35294-0011, USA.


Genetically modified, conditionally-replicating Herpes Simplex Virus Type 1 (HSV-1) vectors for the treatment of malignant glioma have provided encouraging results in the handful of Phase I and Phase II clinical trials conducted to date. In recent years, a number of new strategies have been developed to improve anti-tumor activity of these attenuated vectors, through either introduction of foreign gene inserts to enhance tumor killing through a variety of mechanisms, or through combination with existing treatment regimens, including radiation and/or chemotherapeutics. Another promising new approach has been the engineering of novel oncolytic HSV vectors that retain wildtype replication, but are targeted to tumor cells through a variety of mechanisms. This review summarizes the latest advances in herpesvirus-mediated oncolytic therapies from both preclinical results and clinical trials with oncolytic HSV vectors in patients, and their implication for design of future trials.


C134; G207; HSV1716; M032; Oncolytic HSV therapy; R5141; brain tumor; chimeric HSV; glioma; phase I trial; rQNestin34.5; γ1(34.5).

Free PMC Article

Images from this publication.See all images (1)Free text

Fig. (1)
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk